1. Introduction {#sec1-cancers-12-01785}
===============

MicroRNAs (miRNAs) are noncoding RNA molecules of 18--25 nucleotides in length that regulate the expression of more than one third of human genes \[[@B1-cancers-12-01785],[@B2-cancers-12-01785]\]. Since the discovery of the first miRNA in *Caenorhabditis elegans* \[[@B3-cancers-12-01785]\], these molecules have been found in many organisms and tissue types. miRNAs have been shown to play an important role in cell biology, including differentiation, proliferation and apoptosis \[[@B4-cancers-12-01785]\]. To date, there is evidence that miRNAs regulate different aspects of cancer development \[[@B5-cancers-12-01785]\].

The biogenesis of miRNAs starts with a stem loop precursor created by RNA polymerase II, called primary precursor miRNA (pri-miRNA), that is cleaved by Drosa and DGCR8 proteins to obtain the precursor miRNAs (pre-miRNA) \[[@B6-cancers-12-01785]\]. Finally, the pre-miRNA is cleaved by the Dicer/TRBP complex to create miRNA that represses or degrades the target mRNAs \[[@B7-cancers-12-01785],[@B8-cancers-12-01785]\]. This machinery is altered in cancer cells, perturbing miRNA expression and accelerating the process of tumorigenesis. The discovery of cell-free circulating miRNAs in body fluids (blood, plasma, serum, urine, and cerebrospinal liquid) has put miRNAs in the focus of current research as promising cancer biomarkers \[[@B1-cancers-12-01785],[@B2-cancers-12-01785],[@B7-cancers-12-01785],[@B9-cancers-12-01785],[@B10-cancers-12-01785],[@B11-cancers-12-01785],[@B12-cancers-12-01785]\]. Because the histological examination of tissues is an invasive and comparatively risky procedure, studying miRNAs in biological fluids offers a useful alternative for diagnosis, typing and management of cancer patients.

miRNA expression levels have proven to substantially vary relative to cell types. That makes it possible to use miRNAs to distinguish between cell types \[[@B13-cancers-12-01785]\]. Furthermore, molecular signatures can be useful to differentiate between cancer types in general \[[@B14-cancers-12-01785],[@B15-cancers-12-01785]\]. Another particularity is that these molecules are stable in extracellular environments: for example, they are resistant to pH and heat changes. Nowadays, the use of microarrays, real-time polymerase chain reaction (PCR) and next generation sequencing (NGS) technologies and the creation of databases give us the opportunity to study miRNAs as cancer biomarkers. Several studies have exploited the biomarker properties of miRNAs for cancer detection and classification, using machine learning techniques \[[@B16-cancers-12-01785],[@B17-cancers-12-01785],[@B18-cancers-12-01785],[@B19-cancers-12-01785],[@B20-cancers-12-01785]\].

These works typically analyze thousands of different miRNAs, amounts that would make it impossible for medical experts to manually validate the results or to obtain novel insights. Furthermore, employing thousands of miRNAs in machine learning approaches translates into operating in feature spaces of thousands of dimensions, which nurtures the usual issues linked to the curse of dimensionality. Therefore, in addition to enhancing the interpretability of results, determining small, actionable subselections of features warrants approaches that are insensitive to biases emerging from batch effects (due to processing data from multiple studies, for example), from the use of sets of classifiers that vary in terms of their strengths and weaknesses or just from the nature of their technical foundations. Finding the smallest subset of circulating miRNAs that can identify the presence of cancer or the type of tumor is therefore of utmost practical importance.

In this work, we propose a new methodology to reduce the number of significant circulating miRNAs needed by machine learning techniques to detect and identify cancer types using 16 miRNA datasets from clinical trials. The technique relies on a heterogeneous ensemble of classifiers to provide more robust results than single algorithms or even homogeneous ensembles. The presented approach is first used to identify 10 different types of cancer, and then, in a second experiment, the same technique is applied to separate tumor subtypes in breast cancer. The methodology not only is proven to be effective but also compares favorably to current state-of-the-art techniques.

While a similar technique was presented in \[[@B21-cancers-12-01785],[@B22-cancers-12-01785]\], the approach we propose features several improvements and important innovations that set it apart from previous contributions: (i) previous works did not select for circulating miRNAs, and thus, resulting signatures could not be easily measured in clinical practice; (ii) previous techniques needed extra parameters to be defined by the user (for example, a desired number of features), while the novel approach we propose does not require users to arbitrarily set values for thresholds; and (iii) finally, the amount of data used in the experimental verification greatly increased, getting a total of 16 gene expression omnibus (GEO) datasets.

2. Materials and Methods {#sec2-cancers-12-01785}
========================

First, we compiled a list of circulating miRNAs (mature sequence) based on 5 reviews of circulating miRNAs from cancer studies \[[@B1-cancers-12-01785],[@B2-cancers-12-01785],[@B23-cancers-12-01785],[@B24-cancers-12-01785],[@B25-cancers-12-01785]\]. Next, from this list, we consider only the miRNAs that appear in blood, serum, urine, plasma and saliva. To narrow it further, we focus on the miRNAs that can be detected by Affymetrix platforms Affy-1 (GPL8786), Affy-2 (GPL14613) and Affy-3 (GPL16384). Our choice of restricting to datasets from Affymetrix platforms GPL8786, GPL14613 and GPL16384 has the aim of avoiding the known issue of miRNA expression levels being platform- and technology-dependent \[[@B26-cancers-12-01785],[@B27-cancers-12-01785],[@B28-cancers-12-01785]\]. After this selection, a total of 253 miRNAs remain. The detailed list is included in [Appendix A](#app1-cancers-12-01785){ref-type="app"}.

2.1. Feature Selection {#sec2dot1-cancers-12-01785}
----------------------

As our objective is to select the most meaningful miRNAs to correctly classify the cancer types, we used a recursive ensemble feature selection algorithm where features in our datasets are *expression* values of different miRNAs. The idea behind recursive feature selection is to score each feature depending on its usefulness for the classification process, resorting to a classifier. Features with the lowest scores are then removed, and the process is iterated with the remaining features until the overall classification accuracy drops below a given threshold or when a user-defined number of features is reached. While this technique is effective, it still relies on a classification algorithm to score the features, and a single algorithm might be affected by bias when it assigns scores to the features. A way to reduce the bias is to exploit an ensemble of classification algorithms with different topologies, an idea that is proven to be effective for different problems \[[@B29-cancers-12-01785],[@B30-cancers-12-01785],[@B31-cancers-12-01785]\].

For the ensemble, we selected 8 classifiers from the sci-kit learn toolbox \[[@B32-cancers-12-01785]\] that all were proven to be effective for cancer classification using miRNAs \[[@B18-cancers-12-01785]\] and that are able to score features according to their importance: Stochastic Gradient Descent (SGD), Support Vector Machine classifier (SVC), gradient boosting, random forest, logistic regression, passive aggressive classifier, ridge classifier and bagging. Parameters for each classifier, when different from the default, were taken from \[[@B18-cancers-12-01785]\].

Different algorithms assess feature importance *differently*, as the scoring depends on the computational particularities of the algorithms. Bagging, gradient boosting and random forest use ensembles of classification trees. In these cases, we count the features that appear in the splits of the trees and rank them by frequency. For SVC, SGD, passive aggressive, logistic regression and ridge, the feature importance is given by the absolute value of the coefficients associated to each feature. Therefore, the ranking is based on the value of these coefficients.

As the ranking of each classifier has a different meaning, it is necessary to aggregate this information into an ensemble ranking. Each feature *f* is assigned a simple score $s_{f} = N_{t}/N_{c}$, where $N_{t}$ is the number of times that feature appears among the top *S* over all classifier instances, while $N_{c}$ is the number of classifier instances used. Each classification algorithm has 10 instances, produced by a 10-fold stratified cross-validation ($N_{c} = 8 \times 10 = 80$). The cross-validation is used to increase generality of the results. We selected a stratified cross-validation because it preserves the same ratio of samples for each class in the training and test. Next, the recursive feature algorithm will reduce the number of features *S* by $20\%$ at each iteration. For our experiments, we decided to stop the procedure when the global average accuracy among all classifiers drops to less than $90\%$. The complete procedure is summarized by Algorithm 1. **Algorithm 1:** Recursive ensemble feature selection.![](cancers-12-01785-i001.jpg)

2.2. Cancer Type Classification {#sec2dot2-cancers-12-01785}
-------------------------------

From the gene expression omnibus (GEO) repository \[[@B33-cancers-12-01785]\], we selected 16 datasets for 10 different types of cancer based on clinical studies: Breast (BRCA), esophageal (ESCA), head and neck squamous cell (HNSC), liver hepatocellular (LIHC), prostate (PRCA), glioblastoma (GBM), colorectal (CRC), non-small-cell lung (NSCLC), gastric (GC) and ovarian (OVC), as summarized in [Table 1](#cancers-12-01785-t001){ref-type="table"}. For each dataset, we downloaded the raw data and processed it using the function *Affyrma*() from the Matlab bioinformatics toolbox™. This function processes the probe intensity values using RMA background adjustment, quantile normalization and summarizing procedures and then outputs *expression* (nondimensional). The resulting aggregated dataset for our multi-class classification problem presents 845 samples, 253 features and 10 different tumor classes. Next, we applied Z-score normalization on the dataset to then run the feature selection algorithm in a 10-fold stratified cross-validation scheme.

Then, we compared our results against two current state-of-the-art feature selection methodologies: a homogeneous ensemble classifier exploiting variations of SVC \[[@B29-cancers-12-01785]\] and a feature selection tool based on genetic algorithms, called GALGO \[[@B43-cancers-12-01785]\]. Since each algorithm contains stochastic elements, we run each algorithm 10 times and keep the set of features with the best average accuracy.

The homogeneous ensemble uses several runs of SVC to rank the features by weight and reduces the number of features by a given percentage at each step. In this case, we used the same parameters as for Algorithm 1: 20% step reduction and 90% accuracy as stop parameters. In contrast, for GALGO to obtain a fair comparison, the requested number of features is set to the resulting number of features from the heterogeneous ensemble feature selection classifier.

Finally, we analyzed the genes targeted by the candidate miRNAs using miRNet \[[@B44-cancers-12-01785]\]. The parameters for the miRNet analysis are target genes as main function with a 0.05 *betweenness* filter and pathway enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes \[[@B45-cancers-12-01785]\] (KEGG) and Gene Ontology-Biological Process \[[@B46-cancers-12-01785]\] (GO:BP). Using a *betweenness* filter implies that the genes must be targeted by at least 2 miRNAs.

2.3. Triple-Negative Breast Cancer Classification {#sec2dot3-cancers-12-01785}
-------------------------------------------------

Cancer tumors are divided into tumor subtypes, which can be treated by different strategies depending on their classification. From the available data in the GEO repository, we were able to compile a dataset to assess the possibility of classifying tumor subtypes (luminal A, luminal B, HER2-enriched, triple-negative and normal \[[@B47-cancers-12-01785]\]) in breast cancer (BRCA) using circulating miRNAs. Then, we selected datasets GSE86277, GSE86278, GSE86281 and GSE46823, which are BRCA studies with subtype information. From the BRCA subtypes, triple-negative has the worst prognosis, as it is resistant to hormone therapies \[[@B48-cancers-12-01785]\]. For this reason, we set the labels of the resulting dataset to separate the triple-negative subtype from the rest. Although making an analysis of all the subtypes would have been more interesting, the unbalance in the subtype samples found in the original data makes it impossible; thus, more precisely, the resulting dataset has 139 triple-negative samples and only 44 from the rest of the subtypes, for a total of 183 samples, 253 features and 2 classes (triple-negative/Other).

Next, we applied the function *Affyrma* from the Matlab bioinformatics toolbox™. Then, we applied Z-score normalization on the dataset to run the feature selection algorithm in a 10-fold stratified cross-validation scheme. As in the previous experiment, the feature selection algorithm was set to identify the smallest miRNA subset sufficient to obtain a 90% accuracy. In addition, we compared our results with the 31-miRNA signature proposed by Romero et al. \[[@B35-cancers-12-01785]\] to separate Triple-Negative Breast Cancer (TNBC) from other subtypes of BRCA using miRNA--mRNA integrative analysis in TNBC tumors based on the differential expressed transcripts. It is important to take into consideration that this 31-miRNA list considers noncirculating miRNAs that are not included in our method and could potentially access more information. Finally, we ran miRNet using the candidate miRNAs, as in [Section 2.2](#sec2dot2-cancers-12-01785){ref-type="sec"}.

3. Results {#sec3-cancers-12-01785}
==========

3.1. Cancer Type Classification {#sec3dot1-cancers-12-01785}
-------------------------------

As mentioned in [Section 2.1](#sec2dot1-cancers-12-01785){ref-type="sec"}, each of the classifiers ranks the features differently. When applied to the 253 circulating miRNAs, the top features obtained by each classifier appear as in [Figure 1](#cancers-12-01785-f001){ref-type="fig"}. From visual inspection, it is easy to observe how each classifier ranks the features differently. Nevertheless, the features where the classifiers concur are the most important. From the feature selection algorithm, we reduced the original 253 miRNA to 5, while maintaining an average accuracy of 90% over the selected classifiers ([Figure 2](#cancers-12-01785-f002){ref-type="fig"}).

The resulting most significant 5 features uncovered by the presented algorithm are hsa-let-7a, hsa-miR-23b, hsa-miR-122, hsa-miR-708 and hsa-miR-200c, with seemingly different *expression* levels for each cancer type ([Figure 3](#cancers-12-01785-f003){ref-type="fig"}). For more detailed expression values by cancer type, see [Appendix B](#app2-cancers-12-01785){ref-type="app"}. The classifiers gradient boosting, random forest, SVC and bagging seem to work in a satisfying way for all tumor types using only 5 miRNAs, whereas the rest have issues classifying the types of cancer HNSC, GC and OVC while having better performance when using the full 253 miRNAs, as shown in [Figure 4](#cancers-12-01785-f004){ref-type="fig"}. Interestingly, hsa-let-7 and hsa-miR-200c were also discovered by the homogeneous ensemble while GALGO's performance seems to be less effective and has no miRNAs in common with our approach. From the comparison with GALGO and the homogeneous ensemble classifier with SVC, we can notice how the proposed heterogeneous ensemble classifier outperforms the other feature selection techniques in [Table 2](#cancers-12-01785-t002){ref-type="table"}.

### 3.1.1. Numerical Validation {#sec3dot1dot1-cancers-12-01785}

To further validate our methodology, we split the dataset described in [Section 2.2](#sec2dot2-cancers-12-01785){ref-type="sec"} into a training (90%) and a validation (10%) subsets. Then, we ran 10 instances of the recursive ensemble feature selection algorithm with 90% of the data in a 10-fold cross-validation, which yields the curve in [Figure 5](#cancers-12-01785-f005){ref-type="fig"}.

Next, we selected the smallest signature that provided an accuracy of 90% or above, having as a result hsa-let-7a, hsa-mir-122, hsa-mir-200c, hsa-mir-708 and hsa-mir-23b, the same miRNAs identified in the previous experiment described in [Section 3.1](#sec3dot1-cancers-12-01785){ref-type="sec"}. Then, we tested this signature on the 10% subset, comparing against signatures identified by other approaches: homogeneous ensemble feature selection, GALGO, K-best univariate feature selection (using f-score) and 3 random selected subsets. In addition, we shuffled the test set's labels to verify the proper workings of the classifiers ([Table 3](#cancers-12-01785-t003){ref-type="table"}). Finally, we calculated the Matthews Correlation Coefficient (MCC) for all of the signatures and classifiers \[[@B49-cancers-12-01785]\] ([Table 4](#cancers-12-01785-t004){ref-type="table"}).

From the 10 instances, we then measured the frequency of appearance of miRNAs in the top 5 features for each run. From the original 253 features, only 10 features appear in the top 5 for the heterogeneous recursive ensemble feature selection algorithm, with the frequencies presented in [Figure 6](#cancers-12-01785-f006){ref-type="fig"}. We repeated the same procedure for 10 runs of the homogeneous ensemble feature selection algorithm (feature frequency presented in [Figure 7](#cancers-12-01785-f007){ref-type="fig"}) and GALGO (feature frequency presented in [Figure 8](#cancers-12-01785-f008){ref-type="fig"}). The variability of the output signature for each algorithm reflected that the average and standard deviations for accuracy and MCC for the proposed heterogeneous recursive ensemble feature selection algorithm are better than the homogeneous recursive ensemble feature selection algorithm and GALGO (see [Table 5](#cancers-12-01785-t005){ref-type="table"}).

### 3.1.2. Pathway Analysis {#sec3dot1dot2-cancers-12-01785}

Next, using the 5 candidate miRNAs identified by the proposed approach to separate the tumor type, we ran miRNet to identify the targeted genes, obtaining a total of 1732 genes. After we apply a 0.05 *betweenness* filter, we reduced the list to 156 genes. From these genes, BCL2, CCNG1, COX1, TUBB2A, CELF1 and FOXJ3 are targeted by at least 3 of the 5 miRNAs ([Figure 9](#cancers-12-01785-f009){ref-type="fig"}). Finally, using the function explorer of miRNet, we performed a functional enrichment analysis with a hypergeometric test of the genes from the KEGG database and GO:BP. In [Table 6](#cancers-12-01785-t006){ref-type="table"} and [Table 7](#cancers-12-01785-t007){ref-type="table"}, we show the results of the top 10 functional enrichment analyses for KEGG and GO:BP respectively. The first result in KEGG is the P53 signaling pathway. The P53 protein is a tumor suppressor protein, and it is involved in several anticancer mechanisms \[[@B50-cancers-12-01785]\]. In the GO:BP database, the first result is the cellular response to stress, with 44 of the genes in the pathway; cellular stress is a component of the P53-mediated tumor suppression \[[@B51-cancers-12-01785]\].

3.2. Triple-Negative Breast Cancer Classification {#sec3dot2-cancers-12-01785}
-------------------------------------------------

We ran the heterogeneous ensemble algorithm 10 times, identifying 5 meaningful miRNA features for separating triple-negative BRCA from the other subtypes ([Figure 10](#cancers-12-01785-f010){ref-type="fig"}). The resulting miRNAs are hsa-miR-378\*, hsa-miR-221, hsa-miR-342-3p, hsa-miR-630 and hsa-miR-145. The corresponding expression levels for the identified miRNAs in TNBC and non-TNBC are reported in [Figure 11](#cancers-12-01785-f011){ref-type="fig"}.

Next, we compared the accuracy between classifiers using all 253 miRNAs in the dataset, our 5-miRNA signature, and the 31-miRNA signature proposed by Romero et al. for distinguishing TNBC from other cancers ([Table 8](#cancers-12-01785-t008){ref-type="table"}). From the results, our algorithm outperforms the 31-miRNA signature. In addition, the area under the curve (AUC) of the results ([Figure 12](#cancers-12-01785-f012){ref-type="fig"}) calculated with the gradient boosting classifier is above 90%. This is considered *outstanding* results following the guidelines in \[[@B52-cancers-12-01785],[@B53-cancers-12-01785]\] for clinical use of algorithmic methodologies.

Finally, the results of miRNet found 1294 genes targeted by the 5 miRNAs, with 79 having at least 2 miRNAs in common. From those 79, metastasis gene metadherin-positive (MTDH) is targeted by 4 miRNAs, while type 1 insulin-like growth factor receptor-positive (IGF1R) and cyclin-dependent kinase 6-positive (CDK6) are targeted by 3; see [Figure 13](#cancers-12-01785-f013){ref-type="fig"}. From the enrichment analysis, the most important functional pathway in the KEGG database ([Table 9](#cancers-12-01785-t009){ref-type="table"}) is the *p53 signaling pathway* (the same identified in the previous experiments for separating cancer types), and in GO:BP ([Table 10](#cancers-12-01785-t010){ref-type="table"}), the *negative regulation of cell proliferation*, with 12 of the 79 genes followed by *regulation of cell proliferation* and just *cell proliferation*. These results show an important involvement of cell proliferation in TNBC.

4. Discussion {#sec4-cancers-12-01785}
=============

In this section, we perform an analysis of the candidate miRNAs identified by the proposed feature selection method, using the available literature in cancer studies.

4.1. miRNAs from Cancer Type Classification {#sec4dot1-cancers-12-01785}
-------------------------------------------

The five circulating miRNAs identified by our method as the most informative for cancer type classification are hsa-miR-122, hsa-let-7a, hsa-miR-23b, hsa-miR-708 and hsa-miR-200c.

hsa-miR-122 is a 22-nucleotide RNA molecule that plays an important role in liver functions \[[@B54-cancers-12-01785]\]. It is related to regulation of cholesterol, fatty acid metabolism, and hepatocytes differentiation. Evidence indicates that hsa-miR-122 acts like a tumor suppressor, and its depletion is related to liver inflammation and hepatocellular cancer in mice \[[@B54-cancers-12-01785],[@B55-cancers-12-01785]\]. In breast cancer, hsa-miR-122 has different expression patterns according to the subtype \[[@B56-cancers-12-01785]\]. In addition, miR-122 promotes aggression and epithelial-mesenchymal transition in TNBC \[[@B57-cancers-12-01785]\] and cell survival in radio-resistance cells \[[@B58-cancers-12-01785]\]. High plasma miR-122 levels have been detected in AFP-producing gastric cancer \[[@B59-cancers-12-01785]\].

The let-7 miRNAs show a high evolutionary conservation between organisms. Vertebrates have multiple let-7 isoforms and play an important role in development and tumor suppression \[[@B60-cancers-12-01785]\]. hsa-let-7a is a member of the family and shows a downregulated expression in many tumor types like breast cancer \[[@B61-cancers-12-01785],[@B62-cancers-12-01785]\], lung adenocarcinoma \[[@B63-cancers-12-01785]\] and gastric cancer \[[@B64-cancers-12-01785]\].

hsa-miR-23b is known to target tumor suppressor and cancer promoter genes. hsa-miR-23b is dis-regulated in proliferation, invasion, migration, apoptosis, autophagy and cell survival \[[@B65-cancers-12-01785]\]. As a circulating biomarker, hsa-miR-23b is downregulated in colon cancer measured in plasma \[[@B66-cancers-12-01785]\]. In contrast, it is upregulated in gastric cancer \[[@B67-cancers-12-01785]\], lung cancer \[[@B68-cancers-12-01785]\] and pancreatic cancer \[[@B69-cancers-12-01785]\].

hsa-miR-708, also known as miR-708-5p, is a microRNA encoded within an intron of the ODZ4 gene. It can be found in different tissues with varying expression patterns like reproductive, secretory, muscle, gastrointestinal, nervous and lung \[[@B70-cancers-12-01785]\]. hsa-miR-708 acts as a tumor suppressor or oncogene according to the cancer type. It has been associated with poor prognosis in lung adenocarcinoma \[[@B71-cancers-12-01785]\] and carcinogenesis in colon \[[@B72-cancers-12-01785]\] and bladder \[[@B73-cancers-12-01785]\]. On the other hand, normal levels of hsa-miR-708 decrease cell growth and invasion and increase apoptosis in renal cancer cells \[[@B74-cancers-12-01785]\].

hsa-miR-200c has been identified in lung, gastric, breast, ovarian and endometrial cancer with different expression patterns related to prognosis, aggressiveness and chemoresistance \[[@B75-cancers-12-01785],[@B76-cancers-12-01785]\]. Moreover, hsa-miR-200c is involved in signaling cascades such as TGF-$\beta$, PI3K/Akt, Notch, VEGF, and NF-$\kappa$B making it a candidate biomarker in cancer \[[@B77-cancers-12-01785]\].

The result with the smallest *p*-value from the enrichment analysis in the KEGG dataset identified a strong relationship between the P53 signaling pathway and hsa-miR-122, hsa-let-7a, hsa-miR-23b, hsa-miR-708 and hsa-miR-200c. P53 is an important tumor suppressor that regulates the expression of many genes and is one of the most common mutated genes in cancer. Many miRNAs work as direct and indirect mediators of the P53 activity and the components of its pathway \[[@B78-cancers-12-01785],[@B79-cancers-12-01785]\]. Moreover, the normal function of this tumor suppressor helps the maturation of some miRNAs with growth-suppressing function \[[@B80-cancers-12-01785]\].

On the other hand, the first result in the enrichment analysis in the GO:BP dataset was cellular stress response. In normal cells, there is a balance between the activation of survival and cell death pathways, according to the type and duration of stress \[[@B81-cancers-12-01785]\]. Cancer cells develop molecular mechanisms that facilitate their adaptation to different conditions like oxidative, metabolic, mechanical and genotoxic stresses, avoiding the restriction of the growth and increasing cell proliferation \[[@B82-cancers-12-01785]\]. Importantly, miRNAs have the capacity to modify the stress response in cancer by making cells more susceptible or resistant to chemotherapy \[[@B83-cancers-12-01785]\]. These findings prove that miRNAs play an important role in cancer biology and could be used as powerful circulating biomarkers for diagnosis and prognosis in human malignancies.

4.2. miRNAs from Triple-Negative Breast Cancer Classification {#sec4dot2-cancers-12-01785}
-------------------------------------------------------------

From our analysis, we selected 5 candidate miRNAs that are the most informative to separate cancer TNBC from the other subtypes in BRCA: hsa-miR-378\*, hsa-miR-221, hsa-miR-342-3p, hsa-miR-630 and hsa-miR-145. All of them had already been shown to have potential as circulating cancer biomarkers in cancer studies, e.g., \[[@B84-cancers-12-01785],[@B85-cancers-12-01785],[@B86-cancers-12-01785],[@B87-cancers-12-01785],[@B88-cancers-12-01785],[@B89-cancers-12-01785],[@B90-cancers-12-01785],[@B91-cancers-12-01785],[@B92-cancers-12-01785]\].

hsa-miR-378\* is considered an onco-miRNA for its relationship with tumor growth and cell renewal. It is associated with the progression of breast cancer and the Warburg effect. Furthermore, hsa-miR-378\* is capable of discriminating between breast cancer patients and controls \[[@B84-cancers-12-01785],[@B85-cancers-12-01785]\].

Evidence indicates that hsa-miR-221 is upregulated and that its expression is related to proliferative pathways \[[@B93-cancers-12-01785],[@B94-cancers-12-01785]\]. Several studies have linked the microRNA cluster 221/222 with chemoresistance. The miR-221/222 expression participates in the clinically aggressive basal-like subtype \[[@B95-cancers-12-01785]\] and tamoxifen resistance in ER-positive breast cancer cells \[[@B87-cancers-12-01785],[@B88-cancers-12-01785]\]. Furthermore, this cluster interfers with ER$\alpha$ expression \[[@B87-cancers-12-01785]\] and miR-221/222 knockdown induces growth arrest and apoptosis in cells exposed to tamoxifen \[[@B88-cancers-12-01785]\].

On the other hand, hsa-miR-342-3p expression correlates with ER$\alpha$ mRNA expression and its downregulation is related to tamoxifen resistance. hsa-miR-342-3p plays an important role in the therapy response of tamoxifen in ER-positive breast cancer \[[@B86-cancers-12-01785],[@B89-cancers-12-01785]\]. Moreover, hsa-miR-342-3p activity affects some metabolic pathways like lactate and glucose fluxes in TNBC \[[@B35-cancers-12-01785]\].

hsa-miR-630 is considerably suppressed in BRCA \[[@B90-cancers-12-01785]\]. From in vitro experiments in which hsa-miR-630 mimics was transfected into MDA-MB-231 cells, it could be detected that the expression of hsa-miR-630 was decreased. miR-630 was also capable in inhibiting MDA-MB-231 cell migration and invasion targeting SOX4-3'-UT. Additionally, the SOX4 overexpression plasmid was transfected to further confirm that hsa-miR-630 played its role by downregulation \[[@B96-cancers-12-01785]\].

Finally, hsa-miR-145 acts as a tumor suppressor through the inhibition of different proteins like ERBB3 and RTKN \[[@B91-cancers-12-01785],[@B92-cancers-12-01785]\]. Additionally, hsa-miR-145 cooperates with P53 and has a proapoptotic effect in patients with breast cancer \[[@B97-cancers-12-01785]\].

The miRNet enrichment analysis yields that P53 and the negative regulation of cell proliferation were the signaling pathways mostly involved with these miRNAs. Furthermore, the MTDH, IGF1R and CDK6 genes are targeted by at least 3 of the 5 miRNAs used to identify TNBC. Zare et al. \[[@B98-cancers-12-01785]\] described the interplay of methilation patterns in miRNAs and the epithelial-mesenchymal transition. They identified that some genes like MTDH, IGF1R and CDK6 can be affected by miRNAs and can modify cellular processes in breast cancer.

5. Conclusions {#sec5-cancers-12-01785}
==============

miRNAs are known to play important roles in cellular biology processes such as differentiation, proliferation and apoptosis. Several research lines suggest that miRNAs are involved in different aspects of cancer, and recent studies indicate that there is potential in using their expression profiles as molecular signatures in clinically relevant settings.

miRBase (v22.1) consists of 1917 stem-loop sequences and 2657 mature sequences for human miRNAs \[[@B99-cancers-12-01785]\]. Only some of these 2657 mature sequences are circulating miRNAs, and from that quantity, only 253 can be measured in blood, urine, plasma, serum or saliva (excluding pancreatic juice and cerebrospinal fluid). In this paper, our aim has been to reduce as much as possible the number of miRNAs necessary to classify cancer tumor types and to identify TNBC in BRCA. Our proposed approach consists in applying a recursive ensemble feature selection algorithm to reduce the original 253 miRNAs to 5 for each case study considered while, at the same time, ensuring high-quality classification (\>90% mean classification accuracy over all the ensemble). It is important to state that our results are based on readily available clinical studies from the GEO repository.

Using the identified 5-miRNA signature for tumor classification, the classifier random forest obtains a mean accuracy of 97.61% in a 10-fold cross-validation, providing both results of high quality and a compact, human-interpretable list of miRNAs. When compared to the state-of-the-art in feature selection, our methodology was proven to be better than GALGO and ensemble-based approaches with an homogeneous topology, with a significant statistical difference ($p < 10^{- 4}$ using a standard Welch's T-test). In the TNBC example, the signature obtained by our methodology outperforms the 31-miRNA signature from \[[@B35-cancers-12-01785]\]. These remarkable results stem from the use of machine learning algorithms which are able to consider the influence of groups of features (in this case miRNAs) at the same time, while previous works only employed univariate statistics. Such an outcome is consistent with Mootha et al. \[[@B100-cancers-12-01785]\], which makes the case for considering gene sets instead of individual genes. This methodology can be applied in other problems, such as differentiating between tumors with and without metastasis ([Appendix C](#app3-cancers-12-01785){ref-type="app"}), and it is not restricted to only miRNAs but can also be used in mRNA data. In contrast to other methods such as Saha et al. \[[@B20-cancers-12-01785]\], it is not limited by the number of variables ([Appendix D](#app4-cancers-12-01785){ref-type="app"}).

This analysis is a first step towards assembling new approaches for cancer detection using circulating miRNAs, as measuring only 5 miRNAs levels is not only easier but also more resistant to measurement errors than to try and measure all available miRNAs levels. This research line might help the development of new concepts for prevention, secondary prevention and novel therapies.
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In [Table A1](#cancers-12-01785-t0A1){ref-type="table"}, we present the list of all 253 circulating miRNAs identified in the dataset, using an analysis of the available literature.

cancers-12-01785-t0A1_Table A1

###### 

List of all circulating miRNAs.

  -------------- -------------- ------------- ------------ -------------
  let-7a         miR-140-3p     miR-19b       miR-335      miR-513a-3p
  let-7a\*       miR-141        miR-200a      miR-338-3p   miR-516b
  let-7b         miR-142-3p     miR-200b      miR-338-5p   miR-518b
  let-7c         miR-143        miR-200c      miR-339-3p   miR-520a-3p
  let-7d         miR-144        miR-202       miR-339-5p   miR-548b-5p
  let-7e         miR-145        miR-203       miR-340\*    miR-557
  let-7f         miR-146a       miR-205       miR-342-3p   miR-564
  let-7g         miR-146b-3p    miR-206       miR-345      miR-566
  let-7i         miR-146b-5p    miR-20a       miR-346      miR-571
  miR-1          miR-148a       miR-20b       miR-34a      miR-574-3p
  miR-100        miR-148b       miR-21        miR-34b      miR-574-5p
  miR-101        miR-150        miR-210       miR-361-3p   miR-587
  miR-106b       miR-150\*      miR-212       miR-365      miR-589
  miR-107        miR-151-5p     miR-214       miR-371-5p   miR-595
  miR-10a        miR-152        miR-215       miR-372      miR-601
  miR-10b        miR-155        miR-218       miR-373      miR-616\*
  miR-1182       miR-15a        miR-22        miR-375      miR-618
  miR-122        miR-15b        miR-221       miR-376a     miR-622
  miR-122\*      miR-15b\*      miR-222       miR-376c     miR-625
  miR-1224-5p    miR-16         miR-223       miR-377      miR-625\*
  miR-1229       miR-16-2\*     miR-23a       miR-378      miR-628-3p
  miR-1231       miR-17         miR-23b       miR-378\*    miR-629
  miR-1245       miR-181a       miR-24        miR-379      miR-630
  miR-1246       miR-181a-2\*   miR-25        miR-382      miR-638
  miR-1254       miR-181b       miR-26a       miR-409-3p   miR-646
  miR-125b       miR-181d       miR-26b       miR-409-5p   miR-650
  miR-125b-2\*   miR-182        miR-27a       miR-410      miR-652
  miR-126        miR-1825       miR-27b       miR-411      miR-654-3p
  miR-1260       miR-183        miR-296-5p    miR-421      miR-656
  miR-1268       miR-184        miR-298       miR-423-5p   miR-668
  miR-127-3p     miR-185        miR-299-5p    miR-425      miR-675
  miR-1275       miR-186        miR-29a       miR-425\*    miR-7
  miR-128        miR-187        miR-29b       miR-429      miR-708
  miR-1280       miR-187\*      miR-29c       miR-431      miR-744
  miR-1284       miR-18a        miR-301a      miR-431\*    miR-744\*
  miR-1285       miR-18b        miR-302b      miR-432      miR-760
  miR-1288       miR-18b\*      miR-30a       miR-451      miR-874
  miR-1290       miR-190b       miR-30b       miR-452      miR-885-5p
  miR-1295       miR-191        miR-30c       miR-454      miR-922
  miR-129-5p     miR-192        miR-30c-1\*   miR-454\*    miR-92a
  miR-1304       miR-193a-3p    miR-30d       miR-483-3p   miR-92a-2\*
  miR-130a\*     miR-193b       miR-30e       miR-483-5p   miR-92b
  miR-130b       miR-194        miR-31        miR-484      miR-93
  miR-1323       miR-195        miR-32        miR-486-3p   miR-93\*
  miR-133a       miR-196a       miR-320a      miR-486-5p   miR-936
  miR-133b       miR-196b       miR-320c      miR-487b     miR-939
  miR-134        miR-197        miR-320d      miR-493      miR-942
  miR-138        miR-198        miR-324-3p    miR-494      miR-99a
  miR-138-2\*    miR-199a-3p    miR-326       miR-497      miR-99b
  miR-139-3p     miR-199a-5p    miR-328       miR-502-5p   
  miR-139-5p     miR-19a        miR-331-3p    miR-504      
  -------------- -------------- ------------- ------------ -------------

###### 

Expression levels by cancer type for the 5 miRNAs identified by the proposed approach. Cancer types: breat (BRCA); esophageal (ESCA); head and neck squamous cell (HNSC); liver hepatocelluar (LIHC); prostate (PRCA); gliobastoma (GBM); colorectal (CRC); non-small-cell lung (NSCLC); gastric (GC); ovarian (OVC).

![](cancers-12-01785-g0A1a)

![](cancers-12-01785-g0A1b)

To provide evidence that the proposed methodology can be used not only to classify tumors but also more in general to answer specific questions related to tumors, where miRNAs can be informative, we applied our algorithm to dataset GSE53159 \[[@B101-cancers-12-01785]\], separating metastasized tumors from those which are not. This dataset is composed of 32 samples and 16 colorectal cancer (CRC) samples with liver metastasis and 16 CRC samples without liver metastasis for platform GPL8786. After applying our method, we obtain a 4-miRNA signature, with the differentially expressed hsa-mir-486-3p, hsa-mir-21, hsa-mir-1285, hsa-miR-708 and hsa-mir-638. The final average accuracy is 0.9312, with 0.8625 MCC.

![Ten runs of the heterogeneous ensemble recursive selection algorithm: From the 10 runs, the highest accuracy is given by 4 miRNAs: hsa-mir-486-3p, hsa-mir-21, hsa-mir-1285, hsa-miR-708 and hsa-mir-638.](cancers-12-01785-g0A2){#cancers-12-01785-f0A2}

![Expression levels of selectedmiRNAs: hsa-mir-486-3p, hsa-mir-21, hsa-mir-1285, hsa-miR-708 and hsa-mir-638 in CRC samples with and without metastasis.](cancers-12-01785-g0A3){#cancers-12-01785-f0A3}

While other techniques such as \[[@B20-cancers-12-01785]\] can also be effective to identify signatures for bioinformatic applications, they are usually limited to working with a few hundreds of features. In order to show how our algorithm can be effective even with a large number of features, we apply it to dataset GSE12452 \[[@B102-cancers-12-01785]\] that contains 54,675 features related to messenger RNA (mRNA). This dataset is composed of 41 samples: 31 samples are nasopharyngeal tumor tissue and 10 are normal nasopharyngeal healthy controls for platform GPL570. After applying our methodology, we obtain a signature composed of just one gene, MUC4, differentially expressed to separate tumor and healthy tissue. This is consistent with studies that point out MUC4 as a cancer biomarker \[[@B103-cancers-12-01785],[@B104-cancers-12-01785]\]. Overall, the signature identified has a global accuracy of 1.0, with 1.0 MCC.

![Ten runs of the heterogeneous ensemble recursive selection algorithm: From the 10 runs, the highest accuracy is given by MUC4 gene expression alone.](cancers-12-01785-g0A4){#cancers-12-01785-f0A5}

![Expression levels of MUC4 and difference between tumor tissue and controls.](cancers-12-01785-g0A5){#cancers-12-01785-f0A6}

![Feature importance by classifier: On the horizontal axis, the top features are reported, following their ensemble ranking. The intensity of the color in each square represents the frequency of appearance of that particular feature in the 10 instances of the same classifier produced by cross-validation; the darker the color, the more frequent the appearance of that feature among the most important. It is noticeable how different classifiers rank features differently. For this figure, we report the top 42 features only for visualization purposes.](cancers-12-01785-g001){#cancers-12-01785-f001}

![The results of 10 runs of the recursive ensemble feature selection for cancer type classification: The *x* axis cuts at 5 variables, where all runs cross the 90% average accuracy stop parameter (we computed the subsequent values as a reference).](cancers-12-01785-g002){#cancers-12-01785-f002}

![Heatmap of average expression levels by cancer type for the 5 miRNAs identified by the proposed approach. Cancer types: breat (BRCA); esophageal (ESCA); head and neck squamous cell (HNSC); liver hepatocelluar (LIHC); prostate (PRCA); gliobastoma (GBM); colorectal (CRC); non-small-cell lung (NSCLC); gastric (GC); ovarian (OVC).](cancers-12-01785-g003){#cancers-12-01785-f003}

![Comparison of accuracy by classifier and tumor type for all 253 features (top) and the 5 features identified by the proposed approach (bottom). Cancer types: breast (BRCA); esophageal (ESCA); head and neck squamous cell (HNSC); liver hepatocellular (LIHC); prostate (PRCA); gliobastoma (GBM); colorectal (CRC); non-small-cell lun g (NSCLC); gastric (GC); ovarian (OVC).](cancers-12-01785-g004){#cancers-12-01785-f004}

![Ten runs of the heterogeneous ensemble recursive selection algorithm. From the 10 runs, the minimum number of necessary miRNA to have an accuracy above 90% is 5: hsa-let-7a, hsa-miR-23b, hsa-miR-122, hsa-miR-708, and hsa-miR-200c.](cancers-12-01785-g005){#cancers-12-01785-f005}

![Ten recurrent features in the 5-feature signature for the heterogeneous ensemble feature selection algorithm.](cancers-12-01785-g006){#cancers-12-01785-f006}

![Twelve recurrent features in the 5-feature signature for the homogeneous ensemble feature selection algorithm.](cancers-12-01785-g007){#cancers-12-01785-f007}

![Nine recurrent features in the 5-feature signature for the GALGO.](cancers-12-01785-g008){#cancers-12-01785-f008}

![miRNET targeted genes analysis, showing genes targeted by at least 3 of the 5 miRNAs to classify cancer type: BCL2, CCNG1, COX1, TUBB2A, CELF1 and FOXJ3.](cancers-12-01785-g009){#cancers-12-01785-f009}

![Results of 10 runs of the recursive ensemble feature selection for the TNBC discrimination example: The *x* axis cuts at 5 variables, which is where most evaluations cross the average 0.90 accuracy stop parameter.](cancers-12-01785-g010){#cancers-12-01785-f010}

![Boxplot for the *expression* levels between Triple Negative Breast Cancer (TNBC, cases) and other subtypes (controls).](cancers-12-01785-g011){#cancers-12-01785-f011}

![ROC curve using the gradient boosting classifier to separate Triple Negative Breast Cancer (TNBC) from the rest of the breast cancer subtypes.](cancers-12-01785-g012){#cancers-12-01785-f012}

![miRNET targeted genes analysis, showing genes targeted by at least 3 of the 5 miRNAs to separate Triple Negative Breast Cancer (TNBC) from other breast cancer subtypes: metastasis gene metadherin-positive (MTDH), type 1 insulin-like growth factor receptor-positive (IGF1R) and cyclin-dependent kinase 6-positive (CDK6).](cancers-12-01785-g013){#cancers-12-01785-f013}

cancers-12-01785-t001_Table 1

###### 

Gene expression omnibus (GEO) repository datasets of miRNA cancer studies used in the project for platforms GPL8786, GPL14613 and GPL16384. BRCA: breast cancer; ESCA: esophageal cancer; HSNC: head and neck squamous cell cancer; LIHC: liver hepatocellular cancer; PRCA: prostate cancer; GBM: gliobastoma; CRC: colorectal cancer; NSCLC: non-small-cell lung cancer; GC: gastric cancer; OVC: ovarian cancer.

  Dataset     Samples   Type    Reference                     Class   Platform
  ----------- --------- ------- ----------------------------- ------- ----------
  GSE48088    33        BRCA    \[[@B34-cancers-12-01785]\]   0       GPL14613
  GSE86277    72        BRCA    \[[@B35-cancers-12-01785]\]   0       GPL14613
  GSE86278    49        BRCA    \[[@B35-cancers-12-01785]\]   0       GPL14613
  GSE86281    50        BRCA    \[[@B35-cancers-12-01785]\]   0       GPL16384
  GSE55856    108       ESCA    \[[@B36-cancers-12-01785]\]   1       GPL14613
  GSE34496    44        HSNC    \-                            2       GPL8786
  GSE67138    57        LIHC    \-                            3       GPL8786
  GSE67139    115       LIHC    \-                            3       GPL8786
  GSE116182   64        LIHC    \-                            3       GPL14613
  GSE36802    21        PRCA    \[[@B37-cancers-12-01785]\]   4       GPL8786
  GSE45604    50        PRCA    \[[@B38-cancers-12-01785]\]   4       GPL14613
  GSE104554   38        GBM     \[[@B39-cancers-12-01785]\]   5       GPL14613
  GSE110402   75        CRC     \[[@B40-cancers-12-01785]\]   6       GPL14613
  GSE46729    24        NSCLC   \-                            7       GPL8786
  GSE63121    15        GC      \[[@B41-cancers-12-01785]\]   8       GPL8786
  GSE47841    30        OVC     \[[@B42-cancers-12-01785]\]   9       GPL14613

cancers-12-01785-t002_Table 2

###### 

Comparison of the results of the different feature selection algorithms, reduced from the initial 253 to 5 features to differentiate cancer types.

                        Heterogeneous    Homogeneous         GALGO                                                                                      
  --------------------- ---------------- ------------------- ---------------- ------------------- ---------------- ------------------- ---------------- -------------------
                        $\mathbf{\mu}$   $\mathbf{\sigma}$   $\mathbf{\mu}$   $\mathbf{\sigma}$   $\mathbf{\mu}$   $\mathbf{\sigma}$   $\mathbf{\mu}$   $\mathbf{\sigma}$
  Gradient Boosting     0.9751           0.0134              0.9797           0.0154              0.8374           0.0453              0.975            0.0128
  Random Forest         0.9761           0.0192              0.9854           0.0155              0.8656           0.0383              1                0
  Logistic Regression   0.8877           0.0239              0.8777           0.0281              0.4954           0.0416              1                0
  Passive Aggressive    0.8239           0.0544              0.8144           0.0707              0.4545           0.0590              1                0
  SGD                   0.8937           0.0305              0.8632           0.0362              0.5204           0.0832              0.9941           0.0078
  SVC                   0.9620           0.0197              0.9499           0.0186              0.5308           0.0454              1                0
  Ridge                 0.8083           0.0272              0.6900           0.0173              0.5010           0.0451              0.9977           0.0045
  Bagging               0.9702           0.0193              0.9643           0.0165              0.8418           0.0425              0.9894           0.0121
  Global                0.9121           0.0260              0.8906           0.0273              0.6309           0.0500              0.9945           0.0047

cancers-12-01785-t003_Table 3

###### 

Accuracy on the 10% data for testing the feature selection algorithm: Results for the signatures found by the heterogenous recursive ensemble feature selection algorithm, the homogeneous recursive ensemble feature selection algorithm, K-Best feature selection algorithm using f-score as selection citeria, 3 random feature subsets and a random shuffle of the test labels.

                                           Heterogeneous   Homogeneous   Univariate   GALGO    Random 1   Random 2   Random 3   Shuffle
  ---------------------------------------- --------------- ------------- ------------ -------- ---------- ---------- ---------- ---------
  Gradient Boosting (n_estimators = 300)   0.9412          0.9294        0.9412       0.9176   0.8824     0.8353     0.8000     0.2471
  Random Forest (n_estimators = 300)       0.9412          0.9529        0.9412       0.9059   0.8941     0.8235     0.8235     0.2471
  Logistic Regression                      0.9059          0.8824        0.8588       0.8706   0.6353     0.5412     0.5882     0.2824
  Passive Aggressive                       0.8706          0.7765        0.7176       0.8471   0.4235     0.4118     0.5294     0.1765
  SGD                                      0.8824          0.8588        0.7765       0.7882   0.5294     0.4235     0.3765     0.2353
  SVC(linear)                              0.9765          0.9176        0.8941       0.8588   0.6235     0.6235     0.5412     0.2824
  Ridge                                    0.8118          0.7059        0.7412       0.7059   0.5882     0.4588     0.4000     0.2706
  Bagging (n_estimators = 300)             0.9412          0.9294        0.9176       0.8824   0.8706     0.8471     0.8235     0.2118
  Average                                  0.9089          0.8691        0.8485       0.8471   0.6809     0.6206     0.6103     0.2442

cancers-12-01785-t004_Table 4

###### 

Matthews correlation coefficient values for the 10% data left for testing the feature selection algorithm: The results for the heterogenous recursive ensemble feature selection algorithm, the homogeneous recursive ensemble feature selection algorithm, K-Best feature selection algorithm using f-score as selection citeria, 3 random feature subsets and a random shuffle of the test labels.

                                           Heterogeneous   Homogeneous   Univariate   GALGO    Random 1   Random 2   Random 3   Shuffle
  ---------------------------------------- --------------- ------------- ------------ -------- ---------- ---------- ---------- ---------
  Gradient Boosting (n_estimators = 300)   0.9346          0.9216        0.9346       0.9085   0.8693     0.8170     0.7778     0.1634
  Random Forest (n_estimators = 300)       0.9346          0.9477        0.9346       0.8954   0.8824     0.8039     0.8039     0.1634
  Logistic Regression                      0.8954          0.8693        0.8431       0.8562   0.5948     0.4902     0.5425     0.2026
  Passive Aggressive                       0.8562          0.7516        0.6863       0.8301   0.3595     0.3464     0.4771     0.0850
  SGD                                      0.8693          0.8431        0.7516       0.7647   0.4771     0.3595     0.3072     0.1503
  SVC(linear)                              0.9739          0.9085        0.8824       0.8431   0.5817     0.5817     0.4902     0.2026
  Ridge                                    0.7908          0.6732        0.7124       0.6732   0.5425     0.3987     0.3333     0.1895
  Bagging (n_estimators = 300)             0.9346          0.9216        0.9085       0.8693   0.8562     0.8301     0.8039     0.1242
  Average                                  0.8987          0.8546        0.8317       0.8301   0.6454     0.5784     0.5670     0.1601

cancers-12-01785-t005_Table 5

###### 

$\mu$ and $\sigma$ for accuracy and MCC over 10 runs using the top 5 features, for each algorithm.

                  Accuracy         MCC                                  
  --------------- ---------------- ------------------- ---------------- -------------------
                  $\mathbf{\mu}$   $\mathbf{\sigma}$   $\mathbf{\mu}$   $\mathbf{\sigma}$
  Heterogeneous   0.8840           0.0120              0.8691           0.0156
  Homogeneous     0.8518           0.0183              0.8353           0.0204
  GALGO           0.8227           0.0255              0.8132           0.0338

cancers-12-01785-t006_Table 6

###### 

Top 10 miRNet enrichment analyses in the Kyoto Encyclopedia of Genes and Genomes (KEGG) dataset for miRNAs hsa-miR-122, hsa-let-7a, hsa-miR-23b, hsa-miR-708 and hsa-miR-200c.

  Pathway                    Total   Expected   Hits   Pval
  -------------------------- ------- ---------- ------ ---------------------
  p53 signaling pathway      68      1          10     3.70 × 10${}^{- 6}$
  Pathways in cancer         310     4.57       19     3.70 × 10${}^{- 6}$
  Prostate cancer            87      1.28       11     3.70 × 10${}^{- 6}$
  Glioma                     65      0.958      8      0.000207
  Melanoma                   68      1          7      0.00196
  Bladder cancer             29      0.428      5      0.00196
  Colorectal cancer          49      0.722      6      0.00217
  Chronic myeloid leukemia   73      1.08       7      0.00227
  Focal adhesion             200     2.95       11     0.00327
  Small cell lung cancer     80      1.18       7      0.00327

cancers-12-01785-t007_Table 7

###### 

Top 10 miRNet enrichment analyses in the Gene Ontology-Biological Process (GO:BP) dataset for miRNAs hsa-miR-122, hsa-let-7a, hsa-miR-23b, hsa-miR-708 and hsa-miR-200c.

  Pathway                                                  Total   Expected   Hits   Pval
  -------------------------------------------------------- ------- ---------- ------ ---------------------
  Cellular response to stress                              1620    15.4       44     3.03 × 10${}^{- 8}$
  Positive regulation of cell proliferation                786     7.43       27     1.66 × 10${}^{- 6}$
  Response to hypoxia                                      245     2.31       15     2.53 × 10${}^{- 6}$
  Regulation of cell cycle                                 886     8.37       28     2.53 × 10${}^{- 6}$
  Regulation of cell proliferation                         1430    13.5       36     4.30 × 10${}^{- 6}$
  Response to abiotic stimulus                             876     8.28       27     5.44 × 10${}^{- 6}$
  Negative regulation of cell cycle                        520     4.91       20     1.04 × 10${}^{- 5}$
  Regulation of molecular function                         2250    21.2       46     1.08 × 10${}^{- 5}$
  Regulation of cyclin-dependent protein kinase activity   89      0.841      9      1.40 × 10${}^{- 5}$
  Negative regulation of apoptotic process                 679     6.42       22     2.56 × 10${}^{- 5}$

cancers-12-01785-t008_Table 8

###### 

Accuracy comparison for all classifiers, using all 253 features, the 5-miRNA signature found by the proposed approach, and the 31-miRNA signature from Romero et al. for separating triple-negative from the rest of the BRCA subtypes.

                       5 Feats.                             253 Feats.                           Romero et al.    (31 Feats.)
  -------------------- ---------------- ------------------- ---------------- ------------------- ---------------- -------------------
  **Classifier**       $\mathbf{\mu}$   $\mathbf{\sigma}$   $\mathbf{\mu}$   $\mathbf{\sigma}$   $\mathbf{\mu}$   $\mathbf{\sigma}$
  GradientBoosting     0.9345           0.0523              0.9134           0.0487              0.9239           0.0485
  RandomForest         0.9354           0.0617              0.9459           0.0416              0.9184           0.0432
  LogisticRegression   0.9243           0.0487              0.9406           0.0612              0.8958           0.0643
  PassiveAggressive    0.9076           0.0550              0.9076           0.0778              0.8797           0.0637
  SGDClassifier        0.9085           0.0628              0.8918           0.0770              0.8692           0.0700
  SVC(linear)          0.9243           0.0487              0.9242           0.0655              0.8572           0.0400
  Ridge                0.9079           0.0754              0.9085           0.0533              0.8856           0.0611
  Bagging              0.9295           0.0411              0.9076           0.0544              0.9341           0.0412
  Global               0.9215           0.0557              0.9175           0.0599              0.8955           0.0540
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###### 

Top 10 miRNet enrichment analysis results for miRNAs hsa-miR-378\*, hsa-miR-221, hsa-miR-342-3p, hsa-miR-630 and hsa-miR-145 using the KEGG database.

  Pathway                      Total   Expected   Hits   Pval
  ---------------------------- ------- ---------- ------ ----------
  p53 signaling pathway        68      0.509      6      0.000518
  Pancreatic cancer            69      0.516      6      0.000518
  Glioma                       65      0.486      6      0.000518
  Melanoma                     68      0.509      6      0.000518
  Chronic myeloid leukemia     73      0.546      6      0.000576
  Bladder cancer               29      0.217      4      0.00197
  Cell cycle                   124     0.927      6      0.00821
  Pathways in cancer           310     2.32       9      0.009
  Non-small cell lung cancer   52      0.389      4      0.0133
  Adherens junction            70      0.524      4      0.0368

cancers-12-01785-t010_Table 10

###### 

Top 10 miRNet enrichment analysis results for miRNAs hsa-miR-378\*, hsa-miR-221, hsa-miR-342-3p, hsa-miR-630 and hsa-miR-145 using the GO:BP database.

  Pathway                                            Total   Expected   Hits   Pval
  -------------------------------------------------- ------- ---------- ------ ---------
  negative regulation of cell proliferation          585     2.7        12     0.00631
  regulation of cell proliferation                   1430    6.6        19     0.00631
  cell proliferation                                 1900    8.79       22     0.00674
  G1 phase of mitotic cell cycle                     47      0.217      4      0.00882
  enzyme linked receptor protein signaling pathway   1180    5.43       16     0.00882
  myeloid cell differentiation                       296     1.37       8      0.00882
  G1 phase                                           49      0.226      4      0.00882
  response to endogenous stimulus                    1360    6.3        17     0.0114
  positive regulation of cell proliferation          786     3.63       12     0.0166
  response to organic substance                      2500    11.5       24     0.0166
